2 No-Brainer Healthcare Stocks to Buy Now

The booming obesity-drug market—projected to grow from roughly $30 billion in 2024 to about $130 billion by 2030—is creating major acquisition value and presents two lower-cost ways to gain exposure: Pfizer and Viking Therapeutics. Pfizer paid up to $10 billion for Metsera after abandoning its own oral GLP‑1 for safety reasons, securing a once‑monthly injectable that showed ~11% body‑mass reduction in early trials while offering investors a ~6.8% yield, a stock trading at roughly 8x projected 2027 earnings and benefiting from repeated guidance upgrades and planned $7 billion in cost cuts. Viking’s VK2735 is a pure‑play dual GLP‑1/GIP with a 15.7% mean weight loss in phase‑2 injectable data and a 12.2% oral result marred by high discontinuation at aggressive dosing; with $715 million cash, minimal debt and a $4.3 billion market cap, Viking is a realistic M&A target if tolerability can be improved, underscoring that both commercial muscle and differentiated oral/injectable profiles can capture meaningful share in a multi‑winner market.

Analysis

The article highlights the expanding obesity-drug market, projected to grow from roughly $30 billion in 2024 to about $130 billion by 2030, and uses Pfizer's October 2025 acquisition of Metsera for up to $10 billion as a case study of late-stage M&A pricing; Metsera's once-monthly injectable produced ~11% body-mass reduction over 12 weeks in early data and offers a differentiated dosing cadence versus weekly market leaders. Pfizer abandoned its own oral GLP-1 after April 2025 liver-safety signals, but management has offset that setback with three 2025 guidance raises (now $3.00–$3.15/sh), planned >$7 billion of annual cost cuts by 2027, a ~6.8% dividend yield (quarterly $0.43), and shares trading at ~8x projected 2027 earnings. Viking Therapeutics' VK2735 presents a pure-play alternative: the injectable achieved 15.7% mean weight loss at 13 weeks and entered two phase 3 trials (VANQUISH-1/2) with fast enrollment, while an oral mid-stage study showed 12.2% weight loss but prompted a >30% stock drop due to 28%–38% discontinuation at higher doses. With $715 million cash, minimal debt and a $4.3 billion market cap, Viking is a plausible M&A target if tolerability improves; risks remain around safety/tolerability, regulatory readouts, and competitive pressure from Eli Lilly and Novo Nordisk in a multi-winner market.

Key Decisions for Investors

• Consider Pfizer as a core, income-oriented holding to capture Metsera upside while collecting a ~6.8% yield, but size exposure to reflect integration and regulatory risk given the company scrapped its own oral GLP-1 for liver-safety concerns
• Treat Viking as a higher-risk, event-driven/venture position or M&A-target play given VK2735's 15.7% injectable efficacy, $715 million cash runway and $4.3 billion market cap; limit position size until phase 3 tolerability data and revised dosing demonstrate materially lower discontinuation rates
• Monitor specific near-term triggers: Metsera clinical/regulatory milestones and Pfizer's progress toward the $7 billion cost-reduction target, plus VANQUISH enrollment completion and any announced changes to Viking's oral dosing regimen; use those readouts to add, trim, or hedge positions